Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8807)	2/22/1999 7:07:00 PM
From: Robert S.	Read Replies (1) \| Respond to of 17367

Bluegreen... EVERYONE that has seen papers on BPI or any other antimicrobial peptide is in awe including Robert S. In awe? No. Intrigued? Yes. So now we wait to see if Xoma proves it to work via satisfaction of the FDA. Once again EVERYONE that has seen potential of BPI is in awe, whether or not Xoma can prove it up and make money by proper marketing is a different story. Yes. FDA approval does not guarantee riches. In my opinion Robert S will jump on board if BPI is proven to work and hopefully enough of a class act to limit gloating if BPI fails. Yes. You know when I look at LGND, CORR, and CEPH I see in those recent approvals PLENTY of time to get in after approval. Yes. Even George "slow train leaving" Wohanka and I agree on this issue. On the other hand, if we get explosive article like ENMD did in New York times we may go up rapidly in a matter of hours. Perhaps. The speculation on this board concerning The Lancet article, coupled with the lack of response from Wall Street, should serve as a reminder that what the Xoma myrmidons consider as important is not necessarily what The Street values as important. My opinions only.